Home > Internet > Find Out How Quickly You'll Be Able To Advance The Nutlin-3 Scale

Find Out How Quickly You'll Be Able To Advance The Nutlin-3 Scale

Added: (Wed Sep 13 2017)

Pressbox (Press Release) - ""Purpose Temozolomide (hypothesis): Pelvic fractures are indicators of severe trauma and high energy absorption. They are associated with multiple local or distant concomitant injuries, which explain their high mortality and morbidity. The aim of this study is to investigate the late sequel of traumatic pelvic fractures (PFX) focusing on quality-of-life and sexual-function. Methods: From a database of prospectively documented data, patients who had suffered a PFX and had been treated operatively in our institution from January 2008 to January 2009 were eligible to participate in this study. Ethics committee approval was obtained. Exclusion criteria were patients less than a year postinjury, pathological fractures, patients <18 or>65, and patients with co-morbidities linked to sexual dysfunction. Demographics, injury mechanisms, fracture patterns (Young-Burgess classification), injury severity score (AIS/05-ISS), urogenital injuries and clinical outcome were recorded and analysed. Health-related quality-of-life was assessed using the EuroQol-5D and sexual function using the international index of erectile function and the female sexual function index. Patients were asked to fill the questionnaires twice (once documenting their state prior to their injury and the second time recording their state after the injury). The minimum follow up was 12 months (range 12�C30). Results: Out of 85 patients that met the inclusion criteria, 67 patients (24 females) Bcl-2 inhibitor with a mean age of 44 years (19�C65) consented to participate in this study. Their mean ISS was 25 (9-58), while 5 (7.4%) had isolated fractures. There was shown to be a significant decrease in quality-of-life (p? Submitted by:

Disclaimer: Pressbox disclaims any inaccuracies in the content contained in these releases. If you would like a release removed please send an email to remove@pressbox.co.uk together with the url of the release.